BLOOD REVIEWS
Scope & Guideline
Advancing the frontiers of Hematology and Oncology.
Introduction
Aims and Scopes
- Hematological Malignancies:
The journal covers a wide range of hematological malignancies including leukemia, lymphoma, and myeloma, focusing on their biology, treatment strategies, and patient management. - Coagulation Disorders:
Research on various coagulation disorders, such as hemophilia, thrombocytopenia, and thrombotic conditions, is a key focus, including novel therapeutic approaches and management strategies. - Transfusion Medicine:
Exploration of transfusion practices, adverse reactions, and the evolving landscape of transfusion-related therapies, including the use of blood products and their clinical implications. - Immunotherapy and Targeted Therapies:
Significant emphasis on the development and application of immunotherapies, CAR T-cell therapy, and targeted treatments in hematological disorders, reflecting the shift towards personalized medicine. - Patient-Centered Care:
The journal highlights the importance of quality of life, patient preferences, and shared decision-making in treatment approaches for hematological diseases. - Emerging Technologies:
Coverage of innovative technologies such as artificial intelligence and genomics in the diagnosis and treatment of hematological conditions, aiming to integrate cutting-edge science into clinical practice.
Trending and Emerging
- Gene Therapy and Genetic Modulation:
There is a growing interest in gene therapy as a potential curative approach for various hematological disorders, including sickle cell disease and hemophilia, highlighting advancements in genetic technologies. - Microbiome and Hematology:
Research on the gut microbiome's role in hematological conditions is on the rise, exploring how dysbiosis may impact disease progression and treatment outcomes, indicating a shift towards understanding systemic influences on hematologic health. - Immunotherapy Innovations:
The emergence of novel immunotherapeutic strategies, including bispecific antibodies and checkpoint inhibitors, is a significant trend, reflecting the ongoing transformation in treatment paradigms for hematological malignancies. - Health Equity and Access to Care:
Increasing publications focus on disparities in hematological care, emphasizing the need for equity in access to innovative therapies, particularly among diverse populations. - Patient-Reported Outcomes and Quality of Life:
There is an increasing emphasis on patient-reported outcomes and quality of life measures in research, underscoring the importance of holistic approaches to patient care in hematology. - Artificial Intelligence in Hematology:
The application of artificial intelligence and machine learning in diagnostics, treatment personalization, and monitoring of hematologic diseases is an emerging theme, indicative of the journal's forward-looking approach.
Declining or Waning
- Traditional Chemotherapy Approaches:
With the rise of targeted therapies and immunotherapies, traditional chemotherapy approaches for hematological malignancies are discussed less frequently, as newer treatments gain prominence. - Basic Hematology:
Fundamental topics in hematology that do not directly relate to clinical or translational research are becoming less common, as the journal increasingly favors articles with direct clinical applications or innovative methodologies. - Epidemiological Studies:
While still important, epidemiological studies focusing on rare conditions or those with limited translational impact are less frequently published, as the journal prioritizes studies that offer immediate clinical relevance. - Classic Diagnostic Techniques:
The focus on traditional diagnostic methods is waning in favor of more advanced techniques, such as genomic profiling and machine learning applications in diagnostics. - Older Treatment Modalities:
The exploration of older treatment modalities, particularly those that have been largely replaced by newer therapies, is less common as the field moves toward more effective and innovative treatment options.
Similar Journals
TRANSFUSION AND APHERESIS SCIENCE
Fostering Collaboration and Innovation in Blood HealthTRANSFUSION AND APHERESIS SCIENCE, published by Pergamon-Elsevier Science Ltd, serves as a pivotal platform for researchers and practitioners in the fields of hematology, transfusion medicine, and apheresis. With an ISSN of 1473-0502 and an E-ISSN of 1878-1683, this peer-reviewed journal boasts a respectable Q3 ranking in the Hematology category as of 2023, positioning it within the 45th percentile among its counterparts. Operating from the United Kingdom, it provides comprehensive insights into the latest advancements and methodologies in transfusion practices and apheresis technology, crucial for enhancing patient care and therapeutic strategies. The journal's scope, covering key developments from 1996 to 2024, allows for a deep exploration of historical and emerging trends within the discipline. Moreover, its open access options facilitate widespread dissemination of research findings, fostering collaboration and innovation in the scientific community. For those dedicated to advancing knowledge in hematology, TRANSFUSION AND APHERESIS SCIENCE represents an essential resource, bridging theory and practice in this vital area of healthcare.
EUROPEAN JOURNAL OF HAEMATOLOGY
Pioneering Discoveries in Blood Disorders and TherapiesEUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.
VOX SANGUINIS
Shaping the Future of Hematological ScienceVOX SANGUINIS is a distinguished peer-reviewed journal in the fields of Hematology and Medicine, published by Wiley, a leading academic publisher based in the United Kingdom. With a rich history dating back to its inception in 1952, this journal has consistently provided a platform for innovative research and insightful reviews, advancing the understanding of blood-related disorders and therapies. As evidenced by its robust performance—ranking #57 out of 137 in Scopus for Medicine in Hematology and holding a Q2 classification in both Hematology and miscellaneous Medicine categories—VOX SANGUINIS is recognized for its significant contributions to the scientific community. This journal serves as a vital resource for researchers, professionals, and students alike, fostering knowledge exchange and collaboration within the field. With its ongoing commitment to quality and integrity, VOX SANGUINIS continues to shape the future of hematological research well into 2024 and beyond.
BLOOD
Connecting Scholars, Advancing Knowledge in Blood Research.BLOOD, published by the American Society of Hematology, is a premier peer-reviewed journal in the fields of Biochemistry, Cell Biology, Hematology, and Immunology. With an impressive impact factor and ranking in the top quartiles (Q1) across multiple disciplines, BLOOD is essential reading for researchers and professionals seeking to stay updated on the latest advancements in hematology and related fields. The journal has been a cornerstone of hematological research since its inception in 1946, providing a platform for rigorous scientific inquiry and discourse. Its commitment to publishing high-quality original research, comprehensive reviews, and insightful editorials makes it a vital resource for students, practitioners, and scientists alike. By offering exceptional access to influential publications, BLOOD continues to shape the future of hematology and enhance understanding of blood-related disorders, marking its vital role in advancing both basic and clinical research.
Indian Journal of Hematology and Blood Transfusion
Elevating Knowledge: Your Source for Hematology ExcellenceIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
AMERICAN JOURNAL OF HEMATOLOGY
Advancing Hematological Science Through Rigorous ResearchAmerican Journal of Hematology, published by Wiley, stands as a premier outlet for the dissemination of cutting-edge research in the field of hematology. With a commendable impact factor and ranked #9 out of 137 in the Scopus medicine category, this journal has established a robust presence since its inception in 1976. Operating in the Q1 quartile for hematology, it serves as a crucial resource for researchers, clinicians, and students dedicated to understanding blood disorders and advancing treatment methodologies. While the journal does not currently offer open access options, it remains highly regarded for its rigorous peer-review process and impactful contributions to the scientific community. With coverage extending into 2024, the American Journal of Hematology is committed to fostering innovation and collaboration within the hematological sciences.
Blood Cancer Discovery
Fostering a Global Dialogue on Hematologic AdvancementsBlood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.
TRANSFUSION MEDICINE AND HEMOTHERAPY
Pioneering discoveries in transfusion medicine since 1973.TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.
Hematology
Advancing Hematology: Where Innovation Meets InsightHematology is a distinguished open-access journal published by Taylor & Francis Ltd, dedicated to advancing research and knowledge in the field of hematology. Established in 1996, the journal has continually evolved to meet the needs of a growing community of researchers and practitioners, providing a vital platform for disseminating innovative findings and clinical insights. With its impact factor reflecting a robust commitment to quality scholarship, Hematology has achieved a respectable position in its category as evidenced by its Q3 ranking in the Hematology category and ranks #85 out of 137 in the Scopus index, which positions it in the 38th percentile among its peers. The journal’s open-access policy, initiated in 2019, further enhances its reach and accessibility, allowing a broad audience of professionals, researchers, and students to engage with high-quality research without barriers. By covering a wide range of topics related to blood disorders, treatment methodologies, and emerging therapies, Hematology stands as an essential resource for those dedicated to innovation in this critical area of healthcare.
Blood Research
Exploring the Frontiers of Hematology ResearchBlood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.